The prevalence of metabolic syndrome in Danish patients with HIV infection: The effect of antiretroviral therapy

HIV Medicine

Volumn 10, Issue 6, 2009, Pages 378-387

  Hansen, Birgitte R ^a,b   Petersen, J ^a   Haugaard, S B ^a,b   Madsbad, S ^b   Obel, N ^c   Suzuki, Y ^a   Andersen, O ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Highly active antiretroviral therapy; HIV infection; HIV associated lipodystrophy syndrome; Metabolic syndrome

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADULT; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DENMARK; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK FACTORS; TRIGLYCERIDES;

EID: 67449151649     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00697.x     Document Type: Article

References (43)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. Jerico C, Knobel H, Montero M et al. Metabolic syndrome among HIV-infected patients - prevalence, characteristics, and related factors. Diabetes Care 2005; 28: 132-137.
3. Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002; 25: 1253-1254.
4. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005; 54: 3252-3257.
5. Bonfanti P, Ricci E, de Socio G et al. Metabolic syndrome: A real threat for HIV-positive patients?: Results from the SIMONE Study. J Acquir Immune Defic Syndr 2006; 42: 128-131.
6. Gazzaruso C, Bruno R, Garzaniti A et al. Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome. J. Hypertens 2003; 21: 1377-1382.
7. Estrada V, Martinez-Larrad MT, Gonzalez-Sanchez JL et al. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 2006; 55: 940-945.
8. Jacobson DL, Tang AM, Spiegelman D et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006; 43: 458-466.
9. Bergersen BM, Schumacher A, Sandvik L, Bruun JN, Birkeland K. Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls. Scand J Infect Dis 2006; 38: 682-689.
10. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30: 113-119.
11. Andersen O, Haugaard SB, Andersen UB et al. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism 2003; 52: 1343-1353.
12. Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-139.
13. Lee GA, Lo JC, Aweeka F et al. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006; 43: 658-660.
14. Bernasconi E. Metabolic effects of protease inhibitor therapy. AIDS Read 1999; 9: 254-260, 266.
15. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50: 1378-1388.
16. Graber AL. Syndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated patients with human immunodeficiency virus infection. Endocr Pract 2001; 7: 430-437.
17. Mulligan K, Grunfeld C, Tai VW et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35-43.
18. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045-1052.
19. Petit JM, Duong M, Duvillard L et al. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: A longitudinal study. Horm Metab Res 2000; 32: 367-372.
20. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999; 33: 859-863.
21. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11: 938-939.
22. Montes ML, Pulido F, Barros C et al. Lipid disorders in antiretroviral-naïve patients treated with lopinavir/ ritonavir-based HAART: Frequency, characterization and risk factors. J Antimicrob Chemother 2005; 55: 800-804.
23. Gutierrez F, Padilla S, Navarro A et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ ritonavir-containing regimens. J Acquir Immune Defic Syndr 2003; 33: 594-600.
24. van der Valk M, Kastelein JJ, Murphy RL et al. Nevirapine-containing antiretroviral therapy in HIV-1-infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407-2414.
25. Carr A. Cardiovascular risk factors in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 34 (Suppl 1): S73-S78.
26. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD Study. AIDS 2003; 17: 1179-1193.
27. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-710.
28. Lohse N, Hansen AB, Jensen-Fangel S et al. Demographics of HIV-1 infection in Denmark: Results from the Danish HIV Cohort Study. Scand J Infect Dis 2005; 37: 338-343.
29. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
30. Law M, Puls R, Cheng AK, Cooper DA, Carr A. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naïve adults. Antivir Ther 2006; 11: 179-186.
31. dos Santos Silva I. Cancer Epidemiology: Principles and Methods, 1999. Lyon, France: International Agency for Research on Cancer.
32. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: A population-based study. J Am Coll Cardiol 2007; 49: 2112-2119.
33. Lafeuillade A, Jolly P, Chadapaud S, Hittinger G, Lambry V, Philip G. Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens. J Acquir Immune Defic Syndr 2003; 33: 544-546.
34. Hansen BR, Haugaard SB, Iversen J, Nielsen JO, Andersen O. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: A review. Scand J Infect Dis 2004; 36: 244-253.
35. Grandominico JM, Fichtenbaum CJ. Short-term effect of HAART on blood pressure in HIV-infected individuals. HIV Clin Trials 2008; 9: 52-60.
36. Lee GA, Seneviratne T, Noor MA et al. The metabolic effects of lopinavir/ ritonavir in HIV-negative men. AIDS 2004; 18: 641-649.
37. Fisac C, Virgili N, Ferrer E et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naïve human immunodeficiency virus-infected patients: A randomized controlled study. J Clin Endocrinol Metab 2003; 88: 5186-5192.
38. Noor MA, Seneviratne T, Aweeka FT et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study. AIDS 2002; 16: F1-F8.
39. Noor MA, Lo JC, Mulligan K et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15: F11-F18.
40. Noor MA, Parker RA, O'Mara E et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18: 2137-2144.
41. Athyros VG, Ganotakis ES, Elisaf MS, Liberopoulos EN, Goudevenos IA, Karagiannis A. Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol 2007; 117: 204-210.
42. Qiao Q. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006; 49: 2837-2846.
43. Mosdol A, Witte DR, Frost G, Marmot MG, Brunner EJ. Dietary glycemic index and glycemic load are associated with high-density-lipoprotein cholesterol at baseline but not with increased risk of diabetes in the Whitehall II Study. Am J Clin Nutr 2007; 86: 988-994.